Supernus Pharmaceuticals Inc at Barclays Global Healthcare Conference Transcript
Okay. Thank you very much. Well, good afternoon, everyone. Thank you for joining us this afternoon. We're obviously excited for our next presentation. We're happy to present Supernus Pharmaceuticals here.
For those of you who don't know me, I'll introduce myself, I'm Glen Santangelo, I'm the analyst at Barclays responsible for the specialty pharmaceutical sector amongst some other things. Here joining us from Supernus today is the President and CEO, Jack Khattar. We're very happy to have you here. So thank you very much.
Questions & Answers
Obviously, a lot to talk about in 2025, as you reposition yourself for 2026. So maybe that's a good thing for us to start and sort of dig in. You can talk about some of the accomplishments in 2025, in particular, the Sage Therapeutics acquisition. In July, you had an FDA approval, new product launches. So let me let you start there and talk about how things have sort of evolved in 2025 and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
